​

IDEAYA Biosciences (IDYA) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

IDYA Stock Forecast

IDEAYA Biosciences (IDYA) stock forecast, based on 21 Wall Street analysts, predicts a 12-month average price target of $38.50, with a high of $50.00 and a low of $27.00. This represents a 125.41% increase from the last price of $17.08.

$15 $22 $29 $36 $43 $50 High: $50 Avg: $38.5 Low: $27 Last Closed Price: $17.08

IDYA Stock Rating

IDEAYA Biosciences stock's rating consensus is Buy, based on 21 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 20 Buy (95.24%), 1 Hold (4.76%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 21 1 20 0 Strong Sell Sell Hold Buy Strong Buy

IDYA Price Target Upside V Benchmarks

TypeNameUpside
StockIDEAYA Biosciences125.41%
SectorHealthcare Stocks 35.25%
IndustryBiotech Stocks 86.56%

Price Target Trends

1M3M12M
# Anlaysts--12
Avg Price Target--$55.08
Last Closing Price$17.08$17.08$17.08
Upside/Downside--222.48%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 252111--14
Mar, 252111--14
Feb, 252111--14
Jan, 252111--14
Dec, 243111--15
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 05, 2024Andrew BerensLeerink Partners$27.00$29.58-8.72%58.08%
Oct 24, 2024David DaiUBS$50.00$29.5069.49%192.74%
Sep 25, 2024Graig SuvannavejhMizuho Securities$55.00$31.3775.33%222.01%
Sep 23, 2024Corinne JenkinsGoldman Sachs$48.00$33.7342.31%181.03%
Sep 23, 2024Ben BurnettStifel Nicolaus$66.00$33.7395.67%286.42%
Sep 23, 2024Justin ZelinBTIG$62.00$33.8783.05%263.00%
Sep 10, 2024Ben BurnettStifel Nicolaus$68.00$36.9783.93%298.13%
Aug 27, 2024Yigal NochomovitzCitigroup$58.00$39.8045.73%239.58%
Aug 07, 2024Matthew BieglerOppenheimer$53.00$35.8647.80%210.30%
Jul 10, 2024Gregory RenzaRBC Capital$61.00$37.3363.41%257.14%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Apr 14, 2025OppenheimerOutperformOutperformhold
Nov 05, 2024Leerink PartnersMarket Performdowngrade
Oct 24, 2024UBSBuyinitialise
Oct 15, 2024Cantor FitzgeraldOverweightinitialise
Sep 24, 2024RBC CapitalOutperformOutperformhold
Sep 23, 2024CitigroupBuyBuyhold
Sep 23, 2024Goldman SachsBuyBuyhold
Sep 23, 2024BTIGBuyBuyhold
Sep 23, 2024OppenheimerOutperformOutperformhold
Aug 27, 2024CitigroupBuyBuyhold

Financial Forecast

EPS Forecast

$-5 $-4 $-3 $-2 $-1 $0 $1 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.31$-1.35$-1.32$-1.96$-3.36----
Avg Forecast$-1.43$-1.23$-1.43$-1.91$-2.47$-2.72$-2.65$-2.72$-1.17
High Forecast$-0.61$-0.52$-0.24$-1.73$-2.36$-2.28$-0.84$0.03$-0.19
Low Forecast$-3.01$-2.59$-3.88$-2.07$-2.56$-3.39$-3.98$-4.21$-3.18
Surprise %-8.39%9.76%-7.69%2.62%36.03%----

Revenue Forecast

$0 $140M $280M $420M $560M $700M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$19.54M$27.94M$50.93M$23.39M$7.00M----
Avg Forecast$16.91M$33.97M$53.92M$28.28M$4.67M$16.04M$60.89M$91.67M$295.06M
High Forecast$31.36M$63.01M$124.81M$39.58M$10.80M$37.14M$63.24M$212.21M$683.05M
Low Forecast$9.44M$18.97M$19.30M$19.52M$1.67M$5.74M$58.55M$32.81M$105.61M
Surprise %15.55%-17.74%-5.53%-17.30%50.00%----

Net Income Forecast

$-300M $-230M $-160M $-90M $-20M $50M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-32.27M$-47.53M$-54.81M$-112.96M$-274.48M----
Avg Forecast$-82.06M$-70.62M$-82.47M$-112.96M$-141.31M$-163.02M$-138.49M$-205.28M$-67.49M
High Forecast$-34.95M$-30.08M$-13.63M$-99.56M$-135.52M$-131.19M$-48.12M$1.99M$-11.15M
Low Forecast$-173.25M$-149.09M$-223.44M$-119.24M$-147.10M$-194.84M$-228.86M$-242.18M$-182.86M
Surprise %-60.68%-32.69%-33.54%-94.24%----

IDYA Forecast FAQ

Is IDEAYA Biosciences stock a buy?

IDEAYA Biosciences stock has a consensus rating of Buy, based on 21 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 20 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that IDEAYA Biosciences is a favorable investment for most analysts.

What is IDEAYA Biosciences's price target?

IDEAYA Biosciences's price target, set by 21 Wall Street analysts, averages $38.5 over the next 12 months. The price target range spans from $27 at the low end to $50 at the high end, suggesting a potential 125.41% change from the previous closing price of $17.08.

How does IDEAYA Biosciences stock forecast compare to its benchmarks?

IDEAYA Biosciences's stock forecast shows a 125.41% upside, outperforming the average forecast for the healthcare stocks sector (35.25%) and outperforming the biotech stocks industry (86.56%).

What is the breakdown of analyst ratings for IDEAYA Biosciences over the past three months?

  • April 2025: 14.29% Strong Buy, 78.57% Buy, 7.14% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 14.29% Strong Buy, 78.57% Buy, 7.14% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 14.29% Strong Buy, 78.57% Buy, 7.14% Hold, 0% Sell, 0% Strong Sell.

What is IDEAYA Biosciences’s EPS forecast?

IDEAYA Biosciences's average annual EPS forecast for its fiscal year ending in December 2025 is $-2.72, marking a -19.05% decrease from the reported $-3.36 in 2024. Estimates for the following years are $-2.65 in 2026, $-2.72 in 2027, and $-1.17 in 2028.

What is IDEAYA Biosciences’s revenue forecast?

IDEAYA Biosciences's average annual revenue forecast for its fiscal year ending in December 2025 is $16.04M, reflecting a 129.20% increase from the reported $7M in 2024. The forecast for 2026 is $60.89M, followed by $91.67M for 2027, and $295.06M for 2028.

What is IDEAYA Biosciences’s net income forecast?

IDEAYA Biosciences's net income forecast for the fiscal year ending in December 2025 stands at $-163M, representing a -40.61% decrease from the reported $-274M in 2024. Projections indicate $-138M in 2026, $-205M in 2027, and $-67.49M in 2028.